MCID: CTN015
MIFTS: 56

Cutaneous T Cell Lymphoma

Categories: Rare diseases, Blood diseases, Skin diseases, Immune diseases, Cancer diseases

Aliases & Classifications for Cutaneous T Cell Lymphoma

MalaCards integrated aliases for Cutaneous T Cell Lymphoma:

Name: Cutaneous T Cell Lymphoma 12 14
Cutaneous T-Cell Lymphoma 12 72 49
Lymphoma, T-Cell, Cutaneous 41 69
Lymphoma T-Cell Cutaneous 51
Ctcl 49

Classifications:



External Ids:

Disease Ontology 12 DOID:0060061
MeSH 41 D016410
UMLS 69 C0079773

Summaries for Cutaneous T Cell Lymphoma

NIH Rare Diseases : 49 Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by an abnormal accumulation of cancerous T-cells (a type of white blood cells) in the skin resulting in an itchy, red rash that can thicken or form a tumor. CTCLs belong to a larger group of disorders known asnon-Hodgkin's lymphomas. The most common types are mycosis fungoides and Sézary syndrome. In some cases, cancerous T-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in life-threatening complications. The specific signs and symptoms vary from person to person. The exact cause of these conditions is unknown. Last updated: 9/27/2011

MalaCards based summary : Cutaneous T Cell Lymphoma, also known as cutaneous t-cell lymphoma, is related to mycosis fungoides and adult t-cell leukemia. An important gene associated with Cutaneous T Cell Lymphoma is CTAGE1 (Cutaneous T Cell Lymphoma-Associated Antigen 1), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Istodax and Targretin have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin's lymphoma that has material basis in a mutation of T cells.

Wikipedia : 72 Cutaneous T cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the... more...

Related Diseases for Cutaneous T Cell Lymphoma

Diseases in the Cutaneous T Cell Lymphoma family:

Primary Cutaneous Gamma/delta-Positive T-Cell Lymphoma

Diseases related to Cutaneous T Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 mycosis fungoides 30.3 CCR4 IFNA1 IL15 IL2 IL2RA IL7
2 adult t-cell leukemia 30.0 IL2 IL2RA TNFRSF8
3 hairy cell leukemia 30.0 IFNA1 IL2 IL2RA
4 immune suppression 30.0 IFNG IL2
5 tropical spastic paraparesis 29.9 IFNG IL2 IL2RA
6 sezary's disease 29.9 CCR4 IFNA1 IFNG IL15 IL2 IL2RA
7 dermatitis, atopic 29.7 CCR4 IFNG IL2 IL2RA IL4
8 lymphoma, non-hodgkin, familial 29.6 IL15 IL2 IL2RA TNFRSF8
9 psoriasis 29.6 IFNG IL15 IL2 IL2RA IL4
10 measles 29.6 IFNA1 IFNG IL2 IL4
11 b-cell expansion with nfkb and t-cell anergy 29.4 IL2 IL2RA TIA1
12 leukemia, chronic lymphocytic 29.2 IL2 IL2RA IL4 IL7 TNFRSF8
13 lymphoma, hodgkin, classic 29.2 IL2 IL2RA TIA1 TNFRSF8
14 parapsoriasis 11.4
15 lymphoma 11.2
16 granulomatous slack skin disease 11.1
17 pelvic lipomatosis 10.4 IL15 IL2
18 variola major 10.4 IFNG IL2
19 mycoplasmal pneumonia 10.4 IFNG IL4
20 autoimmune myocarditis 10.3 IFNG IL2
21 virus associated hemophagocytic syndrome 10.3 IL2 IL4
22 berylliosis 10.3 IFNG IL2
23 dermatitis 10.3
24 posterior uveitis 10.3 IFNG IL2 IL2RA
25 intermediate uveitis 10.3 IFNG IL2 IL2RA
26 human immunodeficiency virus infectious disease 10.3 IFNA1 IFNG IL2
27 refractory celiac disease 10.3 IFNG IL15
28 mumps 10.3 IFNG IL2 IL2RA
29 pulmonary sarcoidosis 10.2 IFNG IL2 IL2RA
30 leukocyte disease 10.2 IFNA1 IL2 IL4
31 jak3-deficient severe combined immunodeficiency 10.2 IL15 IL2 IL4
32 lymphomatoid papulosis 10.2
33 rheumatic disease 10.2 IFNA1 IFNG IL2RA
34 alopecia areata 10.2 IFNG IL2 IL2RA
35 leukemia 10.2
36 atopic keratoconjunctivitis 10.2 IFNG IL2 IL4
37 hyperlucent lung 10.2 IFNG IL2RA IL4
38 microscopic colitis 10.2 IFNG IL2 IL4
39 vulvovaginal candidiasis 10.2 IFNG IL2 IL4
40 coccidiosis 10.2 IFNG IL2 IL4
41 folliculitis 10.2 IFNG IL2RA IL4
42 toxic oil syndrome 10.2 IFNG IL2RA IL4
43 paracoccidioidomycosis 10.2 IFNG IL2 IL4
44 leprosy 3 10.2 IFNG IL2 IL4
45 tonsillitis 10.2 IFNG IL2 IL4
46 severe combined immunodeficiency, x-linked 10.2 IL2 IL4 IL7
47 baylisascariasis 10.2 IFNG IL4
48 spondyloarthropathy 10.2 IFNG IL2 IL4
49 parasitic protozoa infectious disease 10.2 IFNG IL2 IL4
50 conjunctivitis 10.1 IFNG IL2 IL4

Graphical network of the top 20 diseases related to Cutaneous T Cell Lymphoma:



Diseases related to Cutaneous T Cell Lymphoma

Symptoms & Phenotypes for Cutaneous T Cell Lymphoma

MGI Mouse Phenotypes related to Cutaneous T Cell Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CCR4 HSD17B11 IFNG IL15 IL2 IL2RA
2 immune system MP:0005387 9.36 IL2RA IL4 IL7 TGFBR1 TIA1 TNFRSF8

Drugs & Therapeutics for Cutaneous T Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Istodax 17 45 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
2
Targretin 17 45 bexarotene VALEANT LUXEMBOURG 12/29/1999
3
UVADEX 17 METHOXSALEN Therakos February 1999
4
Valchlor 17 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013

Drugs for Cutaneous T Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 420)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 153559-49-0 82146
2
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1 298-81-7 4114
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
4
Vorinostat Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 149647-78-9 5311
5
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1 173146-27-5
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
8 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
9 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
10 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
13 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
20 Histone Deacetylase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
21 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2
22 Interferon-alpha Phase 4,Phase 2
23 interferons Phase 4,Phase 2,Phase 1,Early Phase 1
24 Clorazepate Dipotassium Phase 4
25 Folate Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
26 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
27
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
28
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
29
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
30
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
31
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
32
Ofloxacin Approved Phase 3 82419-36-1 4583
33
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
34
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
35
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 55-98-1 2478
36
Etoposide Approved Phase 2, Phase 3, Phase 1, Early Phase 1 33419-42-0 36462
37
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
38
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
39 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
40
Lenalidomide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326
41
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
42
Panobinostat Approved, Investigational Phase 2, Phase 3, Phase 1 404950-80-7 6918837
43
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
44
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
46
Piperacillin Approved Phase 3 66258-76-2 43672
47
Tazobactam Approved Phase 3 89786-04-9 123630
48
Vancomycin Approved Phase 3 1404-90-6 14969 441141
49
Dalteparin Approved Phase 3 9005-49-6
50
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772

Interventional clinical trials:

(show top 50) (show all 487)

# Name Status NCT ID Phase Drugs
1 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
2 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
3 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
4 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
5 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
6 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
7 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
8 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
9 Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study Withdrawn NCT01801670 Phase 4
10 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
12 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
13 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
14 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3 LBH589
15 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
16 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
17 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
18 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
19 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
20 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
21 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
22 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
23 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
24 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
25 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
26 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
27 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
28 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
29 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
30 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
31 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
32 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
33 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
34 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
35 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
36 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
37 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Recruiting NCT01871727 Phase 3 E7777
38 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Recruiting NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
39 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
40 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Active, not recruiting NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate or Bexarotene
41 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Active, not recruiting NCT01728805 Phase 3 Vorinostat
42 PUVA Maintenance Therapy in Mycosis Fungoides Active, not recruiting NCT01686594 Phase 3 8-methoxypsoralen
43 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
44 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3 lenalidomide
45 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
46 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
47 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
48 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
49 Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Unknown status NCT01132989 Phase 2 Lenalidomide
50 Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Unknown status NCT00779896 Phase 1, Phase 2 Tazarotene

Search NIH Clinical Center for Cutaneous T Cell Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: lymphoma, t-cell, cutaneous

Genetic Tests for Cutaneous T Cell Lymphoma

Anatomical Context for Cutaneous T Cell Lymphoma

MalaCards organs/tissues related to Cutaneous T Cell Lymphoma:

38
T Cells, Skin, Bone, Bone Marrow, Liver, B Cells, Lymph Node

Publications for Cutaneous T Cell Lymphoma

Articles related to Cutaneous T Cell Lymphoma:

(show top 50) (show all 883)
# Title Authors Year
1
Accelerated, untargeted metabolomics analysis of cutaneous T-cell lymphoma reveals metabolic shifts in plasma and tumor adjacent skins of xenograft mice. ( 29160924 )
2018
2
E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase 1 study. ( 29363235 )
2018
3
Survival outcomes of primary cutaneous T-cell lymphoma in HIV-infected patients: a national population-based study. ( 29330308 )
2018
4
PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21. ( 29307600 )
2018
5
Effects of neuroimmune axis modulation by aprepitant on anti-pruritic and global disease severity in patients with cutaneous T-cell lymphoma. ( 29352478 )
2018
6
Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data. ( 29440874 )
2018
7
"It's a traumatic illness, traumatic to witness." A qualitative study of the experiences of bereaved family caregivers of patients with cutaneous T-cell lymphoma. ( 29451670 )
2018
8
Highly sensitive virome capture sequencing technique VirCapSeq-VERT identifies partial non-coding sequences but no active viral infection in cutaneous T-cell lymphoma. ( 29427587 )
2018
9
Second primary cutaneous T-cell lymphoma in patients with non-Hodgkin lymphoma: a chicken-or-the-egg issue. ( 29047113 )
2018
10
Serum metabolite profiling of cutaneous T-cell lymphoma based on a multiplatform approach. ( 29413580 )
2018
11
Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients. ( 29107664 )
2018
12
Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. ( 29180399 )
2018
13
Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. ( 29442161 )
2018
14
Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. ( 28625481 )
2017
15
Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma. ( 28803489 )
2017
16
A rare localised nasal CD30<sup>+</sup>primary cutaneous T-cell lymphoma following liver transplantation. ( 29103006 )
2017
17
CUTANEOUS T-CELL LYMPHOMA WITH LYMPH NODE METASTASIS IN AN ADULT ADDAX (ADDAX NASOMACULATUS). ( 28920800 )
2017
18
Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. ( 28872191 )
2017
19
Increased Interleukin-19 Expression in Cutaneous T-Cell Lymphoma and Atopic Dermatitis. ( 28597022 )
2017
20
Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. ( 28805086 )
2017
21
Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute. ( 29166501 )
2017
22
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. ( 28600132 )
2017
23
Cytotoxic CD8+ Granulomatous Cutaneous T-Cell Lymphoma Associated With Human Immunodeficiency Virus Infection: A Diagnostic Challenge. ( 29095738 )
2017
24
Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis ofA Cutaneous T-Cell Lymphoma. ( 29128259 )
2017
25
BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma. ( 28288848 )
2017
26
Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma: reply from authors. ( 28889619 )
2017
27
Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. ( 28853310 )
2017
28
Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155. ( 28395975 )
2017
29
Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma. ( 28711152 )
2017
30
Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma. ( 28889405 )
2017
31
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. ( 29191068 )
2017
32
Distribution and Clustering of Cutaneous T-Cell Lymphoma (CTCL) Cases in Canada During 1992 to 2010. ( 29241349 )
2017
33
Cutaneous T-cell Lymphoma. ( 28802499 )
2017
34
AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair. ( 28884410 )
2017
35
Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma. ( 28685851 )
2017
36
Characterization of a novel canine T-cell line established from a dog with cutaneous T-cell lymphoma. ( 28668559 )
2017
37
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-cell Lymphoma. ( 28729399 )
2017
38
A positive randomised trial in cutaneous T-cell lymphoma. ( 28600131 )
2017
39
Oral bexarotene for post-transplant cutaneous T-cell lymphoma. ( 28748653 )
2017
40
Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-cell Lymphoma. ( 29247659 )
2017
41
Syringotropic Mycosis Fungoides: A Rare Form of Cutaneous T-cell Lymphoma Enabling a Histopathologic "Sigh of Relief." ( 28692463 )
2017
42
miR-155 expression in Primary Cutaneous T-Cell Lymphomas (CTCL). ( 26935979 )
2017
43
Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells. ( 27929746 )
2017
44
Haematological cancer: Brentuximab vedotin - a new standard for cutaneous T-cell lymphoma. ( 28631737 )
2017
45
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. ( 28972015 )
2017
46
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. ( 28103725 )
2017
47
The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. ( 26802931 )
2016
48
Cutaneous T-Cell Lymphoma Misdiagnosed as Lipodermatosclerosis. ( 26914225 )
2016
49
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? ( 27998183 )
2016
50
Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/SAczary syndrome): Use in a community setting. ( 27637355 )
2016

Variations for Cutaneous T Cell Lymphoma

Cosmic variations for Cutaneous T Cell Lymphoma:

9 (show all 18)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM532 KRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,cutaneous T cell lymphoma c.38G>A p.G13D 8
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 2
3 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 2
4 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 2
5 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 2
6 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 2
7 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 2
8 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 2
9 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 2
10 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 2
11 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 2
12 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 2
13 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 2
14 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 2
15 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 2
16 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 2
17 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 2
18 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 2

Copy number variations for Cutaneous T Cell Lymphoma from CNVD:

7 (show all 49)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21732 1 16100000 20300000 Amplification Cutaneous T-cell lymphoma
2 25426 1 189000000 192100000 Deletion Cutaneous T-cell lymphoma
3 38869 10 105700000 111800000 Deletion Cutaneous T-cell lymphoma
4 39996 10 12300000 17300000 Deletion Cutaneous T-cell lymphoma
5 41377 10 17300000 19900000 Amplification Cutaneous T-cell lymphoma
6 42285 10 31400000 34500000 Deletion Cutaneous T-cell lymphoma
7 47113 10 89600000 92900000 Deletion PTEN Cutaneous T-cell lymphoma
8 61605 12 10000000 12600000 Deletion ETV6 Cutaneous T-cell lymphoma
9 71417 12 69800000 74100000 Deletion Cutaneous T-cell lymphoma
10 77639 13 46200000 48900000 Deletion RB1 Cutaneous T-cell lymphoma
11 83022 14 19100000 23600000 Deletion NDRG2 Cutaneous T-cell lymphoma
12 83023 14 19100000 23600000 Deletion ZNF219 Cutaneous T-cell lymphoma
13 97437 16 10300000 12500000 Deletion Cutaneous T-cell lymphoma
14 98274 16 16700000 20500000 Deletion Cutaneous T-cell lymphoma
15 107006 17 11200000 15900000 Deletion MAP2K4 Cutaneous T-cell lymphoma
16 108845 17 23200000 28800000 Amplification DHRS13 Cutaneous T-cell lymphoma
17 108846 17 23200000 28800000 Amplification ERAL1 Cutaneous T-cell lymphoma
18 108847 17 23200000 28800000 Amplification FLOT2 Cutaneous T-cell lymphoma
19 108848 17 23200000 28800000 Amplification PHF12 Cutaneous T-cell lymphoma
20 112029 17 37800000 41900000 Amplification Cutaneous T-cell lymphoma
21 116538 17 6800000 11200000 Deletion TP53 Cutaneous T-cell lymphoma
22 120627 18 2900000 7200000 Amplification Cutaneous T-cell lymphoma
23 123359 18 71300000 76117153 Deletion PARD6G Cutaneous T-cell lymphoma
24 133686 19 6900000 12600000 Deletion Cutaneous T-cell lymphoma
25 142291 2 221300000 224900000 Deletion Cutaneous T-cell lymphoma
26 152036 20 28400000 31500000 Amplification BCL2L1 Cutaneous T-cell lymphoma
27 162458 22 21800000 24300000 Amplification Cutaneous T-cell lymphoma
28 162461 22 21800000 24300000 Deletion Cutaneous T-cell lymphoma
29 171538 3 169200000 172500000 Amplification PRKCI Cutaneous T-cell lymphoma
30 180261 4 102500000 107900000 Amplification Cutaneous T-cell lymphoma
31 180582 4 107900000 114100000 Amplification Cutaneous T-cell lymphoma
32 181002 4 114100000 120600000 Amplification Cutaneous T-cell lymphoma
33 184833 4 182600000 187300000 Deletion Cutaneous T-cell lymphoma
34 186902 4 40900000 45600000 Deletion Cutaneous T-cell lymphoma
35 190065 4 82600000 84300000 Deletion Cutaneous T-cell lymphoma
36 203973 6 104800000 113900000 Deletion Cutaneous T-cell lymphoma
37 206027 6 135200000 139100000 Deletion Cutaneous T-cell lymphoma
38 211016 6 31900000 33600000 Deletion Cutaneous T-cell lymphoma
39 212690 6 40600000 45200000 Deletion VEGFA Cutaneous T-cell lymphoma
40 222425 7 15200000 19500000 Deletion Cutaneous T-cell lymphoma
41 225996 7 53900000 57400000 Amplification EGFR Cutaneous T-cell lymphoma
42 233736 8 127300000 131500000 Amplification MYC Cutaneous T-cell lymphoma
43 237881 8 27400000 29700000 Deletion Cutaneous T-cell lymphoma
44 238080 8 29700000 38500000 Deletion Cutaneous T-cell lymphoma
45 239603 8 39900000 43200000 Deletion Cutaneous T-cell lymphoma
46 243701 8 87200000 93500000 Amplification Cutaneous T-cell lymphoma
47 244139 8 93500000 99100000 Deletion Cutaneous T-cell lymphoma
48 249980 9 19900000 25500000 Deletion CDKN2A Cutaneous T-cell lymphoma
49 255727 9 83400000 86100000 Deletion Cutaneous T-cell lymphoma

Expression for Cutaneous T Cell Lymphoma

Search GEO for disease gene expression data for Cutaneous T Cell Lymphoma.

Pathways for Cutaneous T Cell Lymphoma

Pathways related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 CCR4 HDAC9 IFNA1 IFNG IL15 IL2
2
Show member pathways
13.49 IFNA1 IFNG IL15 IL2 IL2RA IL4
3
Show member pathways
13.36 CCR4 IL15 IL2 IL2RA IL4 IL7
4
Show member pathways
13.31 IFNA1 IFNG IL15 IL2 IL2RA IL4
5
Show member pathways
13.25 CCR4 IL15 IL2 IL2RA IL4 IL7
6
Show member pathways
12.92 HDAC9 IFNA1 IL2 IL2RA IL4 IL7
7
Show member pathways
12.81 IFNA1 IFNG IL15 IL2 IL2RA IL4
8
Show member pathways
12.74 IFNA1 IFNG IL15 IL2 IL2RA IL4
9
Show member pathways
12.71 IL15 IL2 IL2RA IL4 IL7
10 12.65 IFNA1 IFNG IL15 IL2 IL2RA IL4
11
Show member pathways
12.54 IFNG IL2 IL2RA IL4 TGFBR1
12 12.51 IFNA1 IFNG IL2 IL2RA IL4 TNFRSF8
13
Show member pathways
12.45 IFNA1 IFNG IL2 IL4
14 12.35 IL15 IL2 IL2RA TGFBR1
15
Show member pathways
12.08 IFNA1 IFNG IL15 IL2 IL4
16
Show member pathways
12.08 IFNA1 IFNG IL15 IL2 IL2RA IL4
17
Show member pathways
11.92 IFNG IL2 IL2RA IL4
18 11.82 IL2RA IL4 IL7
19 11.8 IFNA1 IFNG IL15 IL2 IL2RA
20 11.8 IFNG IL15 IL2 IL2RA IL4 IL7
21
Show member pathways
11.79 IFNG IL4 TGFBR1
22 11.73 IFNG IL2 IL4
23
Show member pathways
11.72 IFNG IL2 IL2RA IL4
24
Show member pathways
11.64 IL2 IL2RA IL4
25
Show member pathways
11.59 IFNG IL2 IL2RA
26 11.42 IFNG IL2 IL2RA IL4
27 11.34 IFNG IL15 IL2 IL2RA IL4 IL7
28
Show member pathways
11.29 IFNG IL15 IL2 IL2RA
29 11.22 IFNG IL2 IL2RA IL4
30 11.18 IFNG IL2 IL2RA
31 11.17 IFNG IL15 IL4 IL7
32 11.15 IL15 IL2 IL4 IL7
33 11.14 IFNG IL2 IL4
34 10.89 IL4 TGFBR1
35 10.5 IFNG IL15 IL2 IL4 IL7

GO Terms for Cutaneous T Cell Lymphoma

Biological processes related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.96 IFNG IL15 IL2 IL7 TGFBR1
2 inflammatory response GO:0006954 9.88 CCR4 HDAC9 IL15 IL2RA TNFRSF8
3 regulation of receptor activity GO:0010469 9.8 IFNA1 IFNG IL15 IL2 IL4 IL7
4 B cell differentiation GO:0030183 9.7 HDAC9 IFNA1 IL4
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 IFNG IL15 IL2
6 humoral immune response GO:0006959 9.67 IFNA1 IFNG IL7
7 positive regulation of B cell proliferation GO:0030890 9.58 IL2 IL4 IL7
8 immune response GO:0006955 9.56 CCR4 IFNG IL15 IL2 IL2RA IL4
9 positive regulation of interleukin-17 production GO:0032740 9.55 IL15 IL2
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.54 IL2 IL4
11 negative regulation of lymphocyte proliferation GO:0050672 9.46 IL2 IL2RA
12 positive regulation of T cell proliferation GO:0042102 9.46 IL15 IL2 IL2RA IL4
13 positive regulation of tissue remodeling GO:0034105 9.43 IL15 IL2
14 regulation of regulatory T cell differentiation GO:0045589 9.43 IFNG IL2 IL2RA
15 regulation of T cell homeostatic proliferation GO:0046013 9.37 IL2 IL2RA
16 positive regulation of T cell differentiation GO:0045582 8.92 IL2 IL2RA IL4 IL7

Molecular functions related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 IFNA1 IFNG IL15 IL2 IL4 IL7
2 cytokine receptor binding GO:0005126 8.92 IFNA1 IL15 IL4 IL7

Sources for Cutaneous T Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....